Pulse Biosciences Inc Common Stock (DE)
PLSE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PLSE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLSE
Pulse Biosciences Inc is a clinical-stage medical technology company developing its Nano-Pulse Stimulation (NPS) platform for applications in electrophysiology and oncology, with a lead focus on treating atrial fibrillation and solid tumors.
Key risk: Financing dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for Pulse Biosciences Inc Common Stock (DE).
Pulse Biosciences Inc is a clinical-stage medical technology company developing its Nano-Pulse Stimulation (NPS) platform for applications in electrophysiology and oncology, with a lead focus on treating atrial fibrillation and solid tumors.
- Cash and cash equivalents were $101.6 million as of June 30, 2026, which management believes is sufficient to fund projected operating requirements for at least the next twelve months [sec_mda · as of 2026-08-06].
- The company has incurred significant operating losses since inception and generated only limited revenue from product sales to date [sec_mda · as of 2026-02-19].
- Majority stockholder Robert Duggan and CEO Paul LaViolette have provided substantial funding, including a $12.9 million at-the-market sale in May 2026 [sec_mda · as of 2026-05-14].
- The company's NPS technology is being evaluated for treating atrial fibrillation (AF), tumors, and nodules, with potential partnership opportunities to develop additional applications [sec_mda · as of 2025-11-05].
- Net loss for the six months ended June 30, 2026 was $24.7 million, and shareholders' equity stood at $80.7 million as of that date [latest reported financials].
What works
- Cash position of $101.6 million as of June 30, 2026 provides a multi-year runway to advance clinical programs without near-term financing pressure [sec_mda · as of 2026-08-06].
- Majority stockholder Robert Duggan has repeatedly demonstrated willingness to invest significant capital, including $60.0 million in a 2024 rights offering and $12.9 million in a May 2026 ATM sale [sec_mda · as of 2025-11-05][sec_mda · as of 2026-05-14].
- The NPS platform is versatile, with potential applications across electrophysiology and oncology, and the company may seek partnerships to expand into additional medical disciplines [sec_mda · as of 2025-11-05].
What to weigh
- The company has not yet achieved profitability or positive operating cash flows and has only generated limited product revenue to date [sec_mda · as of 2026-02-19].
- Future financing is uncertain; there is no assurance that additional capital or revenue-generating collaborations will be available on acceptable terms, which could force delays or scale-backs of operations [sec_mda · as of 2026-08-06][sec_mda · as of 2026-05-14].
- Reliance on a single majority stockholder for funding creates concentration risk; Mr. Duggan may not elect to participate in future fundraisings [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash position and runway
“As of June 30, 2026, we had cash and cash equivalents of $101.6 million. We believe that our existing financial resources are sufficient to fund our projected operating requirements for at least the next twelve months from the filing date of this Quarterly Report on Form 10”
SEC MD&A · August 6, 2026
Majority stockholder funding
“On May 11, 2026, we sold 675,233 shares of common stock in aggregate for net proceeds of approximately $12.9 million, after deducting discounts, commissions, and offering costs, pursuant to a sales agreement with TD Securities LLC under an at-the-market offering program, to Mr. Robert Duggan, our majority stockholder and Co-Chairman, and Mr. Paul LaViolette, our Chief Executive Officer and Co-Chairman”
SEC MD&A · May 14, 2026
Uncertainty of future financing
“There can be no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed or that we will be able to obtain financing or enter into a collaboration on”
SEC MD&A · February 19, 2026
Operating losses and limited revenue
“To date, we have generated only limited revenue from product sales and we have incurred significant operating losses each year since our inceptio”
SEC MD&A · February 19, 2026
Risks & what to watch (4)›
Key risks
- Financing dependency — Company relies on future financing or collaborations; no assurance of availability on acceptable terms [sec_mda · as of 2026-08-06]
- No profitability — Has not achieved profitability or positive cash flow; limited product revenue to date [sec_mda · as of 2026-02-19]
- Majority stockholder concentration — Robert Duggan may not participate in future fundraisings, creating funding risk [sec_mda · as of 2026-08-06]
- Clinical and regulatory uncertainty — If NPS technology fails to treat AF, tumors, or nodules, operations may be scaled back or eliminated [sec_mda · as of 2026-05-14]
What to watch
- Ability to secure additional financing or revenue-generating collaborations in the near term [sec_mda · as of 2026-08-06]
- Clinical progress of NPS technology in atrial fibrillation and tumor/nodule treatments [sec_mda · as of 2025-11-05]
- Continued support from majority stockholder Robert Duggan in future fundraisings [sec_mda · as of 2026-08-06]
- Cash burn rate and whether the $101.6 million runway extends beyond twelve months [sec_mda · as of 2026-08-06]
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Pulse Biosciences Inc Common Stock (DE) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pulse Biosciences Inc Common Stock (DE) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
16.5 months
D/E 0.16
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
94
Total value held
$166.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,631,704 | $35.2M |
| blackrock, inc. | 1,339,778 | $28.9M |
| bank of america corp /de/ | 866,061 | $18.7M |
| geode capital management, llc | 491,946 | $10.6M |
| massachusetts financial services co /ma/ | 462,899 | $10.0M |
| state street corp | 456,927 | $9.9M |
| balyasny asset management l.p. | 265,164 | $5.7M |
| griffin asset management, inc. | 225,177 | $4.9M |
| northern trust corp | 187,272 | $4.0M |
| citadel advisors llc | 168,050 | $3.6M |
Showing top 10 of 94 institutional holders of Pulse Biosciences Inc Common Stock (DE). Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 16.2%
- Days to cover
- 11.2
- Shares short
- 2,915,409
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLSE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pulse Biosciences Inc Common Stock (DE)?
Pulse Biosciences Inc is a clinical-stage medical technology company developing its Nano-Pulse Stimulation (NPS) platform for applications in electrophysiology and oncology, with a lead focus on treating atrial fibrillation and solid tumors.
Who is the CEO of Pulse Biosciences Inc Common Stock (DE)?
Mr. Paul Arthur LaViolette M.B.A. is the chief executive officer of Pulse Biosciences Inc Common Stock (DE) (PLSE).
Where is Pulse Biosciences Inc Common Stock (DE) headquartered?
Pulse Biosciences Inc Common Stock (DE) (PLSE) is headquartered in Miami, FL, United States.
What therapeutic areas does Pulse Biosciences Inc Common Stock (DE) focus on?
Pulse Biosciences Inc Common Stock (DE) develops therapies across Cardiovascular, Dermatology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.